Brady Corp's Q4 2025: Contradictions Emerge on Tariff Mitigation, R&D, Economic Outlook, and Regional Performance

Generated by AI AgentAinvest Earnings Call Digest
Thursday, Sep 4, 2025 12:53 pm ET2min read
BRC--
Aime RobotAime Summary

- Brady Corp reported Q4 adjusted EPS of $1.26 (+5.9% YoY) with 2.4% organic sales growth driven by Americas/Asia and R&D investments.

- FY26 guidance forecasts $4.85–$5.15 adjusted EPS despite $8–$12M tariff impacts, offset by reshoring and supply chain reconfiguration.

- R&D spending rose 31% in Q4, focusing on high-margin materials and safety products, with acquisitions like Gravitec enhancing innovation.

- Europe/Australia challenges persist, but restructuring aims to improve margins, while Q4 cash flow weakness linked to inventory builds.

The above is the analysis of the conflicting points in this earnings call

Date of Call: None provided

Financials Results

  • Revenue: Not disclosed; total sales up 15.7% YOY (organic +2.4%, acquisitions +11.3%, FX +2.0%)
  • EPS: Adjusted diluted EPS $1.26, up 5.9% YOY; GAAP diluted EPS $1.04 vs $1.15 prior year
  • Gross Margin: 50.4%, down from 51.6% YOY; excluding $1.9M reorg costs in COGS, 50.9%
  • Operating Margin: Not disclosed

Guidance:

  • FY26 GAAP EPS expected at $4.55–$4.85 (+15.5%–23.1% YOY).
  • FY26 adjusted EPS expected at $4.85–$5.15 (+5.4%–12% YOY).
  • FY26 organic sales growth: low single digits.
  • Tax rate ~21%.
  • Depreciation & amortization ~ $42M; Capex ~ $40M.
  • Incremental tariff impact in FY26: ~$8–$12M vs FY25 (more weighted to 1H); mitigation actions included in outlook.
  • Risks: stronger USD, inflation not offset in time, and macro slowdown.

Business Commentary:

* Sales Growth and Profitability: - Brady CorporationBRC-- reported a record high adjusted EPS of $1.26 per share for Q4, up 5.9% from the previous year, and organic sales growth of 2.4% in the quarter. - Growth was driven by strong performance in the Americas and Asia region, acquisitions, and increased investment in R&D.

  • Regional Performance:
  • The Americas and Asia region reported strong organic sales growth of 4.3% in Q4, contributing significantly to the company's overall growth, despite a decline in Europe and Australia.
  • This growth was supported by robust performance in wire identification and printer products, particularly in data centers and aerospace and defense sectors.

  • Impact of Tariffs and Mitigation Strategies:

  • Brady faced an incremental tariff expense of approximately $2 million in Q4 and $7 million in fiscal year 2025.
  • The company is implementing mitigating strategies such as reshoring and reconfiguring the supply chain to offset tariff impacts, with additional mitigations planned for fiscal year 2026.

  • R&D Investments:

  • R&D investment increased by 31% in Q4, driven by organic business investments and acquisitions like Gravitec and Hunais Microfluidic Solutions.
  • The focus of these investments is to drive innovation and product differentiation, particularly in high-performance materials and safety products.

Sentiment Analysis:

  • Management highlighted a record quarterly and annual adjusted EPS, fifth consecutive year of record EPS, and strong Americas/Asia growth. They guided to higher FY26 EPS despite macro and tariff headwinds, citing cost reductions and tariff mitigation. Europe/Australia remain challenging, but restructuring positions the business for improved profitability.

Q&A:

  • Question from Steve Verrazzani (Sidoti): Guidance implies strong EPS growth and margin expansion despite headwinds. How will you achieve this?
    Response: Margin expansion driven by recent cost reductions and tariff mitigation (pricing, supply-chain/reshoring actions), with improving traction of current products.

  • Question from Steve Verrazzani (Sidoti): Why was Q4 free cash flow weak, and what does it mean for FY26 cash flow given higher Capex?
    Response: Lower Q4 cash flow stemmed from inventory builds tied to multiple facility moves; remaining cash costs will taper and be largely done by end of Q1.

  • Question from Steve Verrazzani (Sidoti): Will R&D stay above 5%, and are recent acquisitions dilutive near term?
    Response: Funai microfluidics is a longer-term R&D platform; MECO should be immediately accretive with cost overlaps; R&D to remain a priority near/above ~5%.

  • Question from Keith Housum (Northcoast Research): Will R&D revert to ~5% of sales or is this a new normal?
    Response: No strict percent target; investments are opportunity-driven. Highly engineered products carry higher gross margins, so elevated R&D can improve profitability.

  • Question from Keith Housum (Northcoast Research): Is the $8–$12M incremental tariff impact front-half loaded and included in guidance?
    Response: Yes; impacts skew to H1 as price actions phase in, and mitigation efforts are embedded in the FY26 outlook.

  • Question from Keith Housum (Northcoast Research): What end markets are driving printer/consumables (just under 40% of sales) growth?
    Response: Wire markers are strongest, led by data centers and defense/aerospace; construction contributes but is smaller.

Descubre qué cosas los ejecutivos no quieren revelar durante las llamadas de conferencia.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet